Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

Rheumatoid arthiritis - adalumumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab [ID537]

NICE has received 3 appeals against the Final Appraisal Determination on the above technology from the following organisations:

• British Society for Rheumatology (BSR)
• Merck Sharp Dohme (MSD)
• National Rheumatoid Arthritis Society (NRAS)

Merck Sharp Dohme have withdrawn their appeal and will not attend the hearing.

The Appeal hearing is taking place on Thursday 26 November 2015 at NICE, Level 1a City Tower, Piccadilly Plaza, Manchester M1 4BD at 11.30am. 

This page was last updated: 26 November 2015